march 19th tirzepatide Circle Lilly's next-gen obesity drug shows

A healthcare provider can explain the different insurance options and navigate the insurance process

Medicare GLP-1 Coverage for Weight Loss Starts July 2026: What You Need to Know CNCs Complete Medicare Guide (Updated July 1, 2026) For the full, up-to-date reference on the Medicare GLP-1 Bridge program including who qualifies, what it costs, the CNC prior authorization process, and how to start see our Medicare Weight Loss Coverage guide

At week 26, LDL-C was reduced by 19.0% (-36.0% to -1.9%, p=.029) in the tirzepatide 15 mg group compared to placebo while it was reduced by 17.8% (-33.7% to -2.0%, p= 0.028) in the dulaglutide 1.5 mg group compared to placebo though differences between the 2 medications were not seen [60]

Tirzepatide represents the vanguard of this movement, acting as a dual agonist for both GIP and GLP-1 receptors

192 , 5659 (2011) Thompson, R.A., Isin, E.M., Li, Y., Weaver, R., Weidolf, L., Wilson, I., Claesson, A., Page, K., Dolgos, H., Kenna, J.G.: Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development